Patents by Inventor Stephane Ciblat

Stephane Ciblat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120208876
    Abstract: The invention relates to compounds, to compositions comprising the same and uses thereof for the prevention or treatment of pain, e.g neuropathic pain while having neutral or beneficial effect on metabolic parameters.
    Type: Application
    Filed: November 4, 2011
    Publication date: August 16, 2012
    Inventors: Xianqi KONG, Nigel LEVENS, Serge LAMOTHE, Mohamed ATFANI, Stephane CIBLAT, Lucie JETTE
  • Publication number: 20110263534
    Abstract: The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.
    Type: Application
    Filed: August 11, 2006
    Publication date: October 27, 2011
    Inventors: Yannick Stephane Rose, Stephane Ciblat, Ting Kang, Adel Rafai Far, Evelyne Dietrich, Yanick Lafontaine, Ranga Reddy
  • Publication number: 20100113333
    Abstract: The present invention is directed to antimicrobial compounds which have an affinity for binding bones. More particularly, the invention is directed to phosphonated derivatives of glycopeptide or lipoglycopeptide antibiotics. These compounds are useful as antibiotics for the prevention or treatment of bone and joint infections, especially for the prevention and treatment of osteomyelitis.
    Type: Application
    Filed: December 21, 2007
    Publication date: May 6, 2010
    Applicant: TARGANTA THERAPEUTICS, INC.
    Inventors: Kelly Tanaka, Adel Rafai Far, Stephane Ciblat, Evelyne Dietrich
  • Publication number: 20080146642
    Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.
    Type: Application
    Filed: October 12, 2007
    Publication date: June 19, 2008
    Inventors: Xianqi Kong, Mohamed Atfani, Benoit Bachand, Abderrahim Bouzide, Stephane Ciblat, Sophie Levesque, David Migneault, Isabelle Valade, Xinfu Wu, Daniel Delorme